Therapeutic siRNA for drug-resistant HER2-positive breast cancer

Shenda Gu, Zhi Hu, Worapol Ngamcherdtrakul, David J. Castro, Jingga Morry, Moataz M. Reda, Joe Gray, Wassana Yantasee

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

HER2 is overexpressed in about 20% of breast cancers and contributes to poor prognosis. Unfortunately, a large fraction of patients have primary or acquired resistance to the HER2-targeted therapy trastuzumab, thus a multi-drug combination is utilized in the clinic, putting significant burden on patients. We systematically identified an optimal HER2 siRNA from 76 potential sequences and demonstrated its utility in overcoming intrinsic and acquired resistance to trastuzumab and lapatinib in 18 HER2-positive cancer cell lines. We provided evidence that the drug-resistant cancer maintains dependence on HER2 for survival. Importantly, cell lines did not readily develop resistance following extended treatment with HER2 siRNA. Using our recently developed nanoparticle platform, systemic delivery of HER2 siRNA to trastuzumab-resistant tumors resulted in significant growth inhibition. Moreover, the optimal HER2 siRNA could also silence an exon 16 skipped HER2 splice variant reported to be highly oncogenic and linked to trastuzumab resistance.

Original languageEnglish (US)
Pages (from-to)14727-14741
Number of pages15
JournalOncotarget
Volume7
Issue number12
DOIs
StatePublished - Mar 22 2016

Fingerprint

Small Interfering RNA
Breast Neoplasms
Pharmaceutical Preparations
Cell Line
Neoplasms
Drug Combinations
Therapeutics
Nanoparticles
Exons
Survival
Trastuzumab
Growth

Keywords

  • Breast cancer
  • Her2
  • Nanoparticles
  • SiRNA
  • Trastuzumab resistance

ASJC Scopus subject areas

  • Oncology

Cite this

Gu, S., Hu, Z., Ngamcherdtrakul, W., Castro, D. J., Morry, J., Reda, M. M., ... Yantasee, W. (2016). Therapeutic siRNA for drug-resistant HER2-positive breast cancer. Oncotarget, 7(12), 14727-14741. https://doi.org/10.18632/oncotarget.7409

Therapeutic siRNA for drug-resistant HER2-positive breast cancer. / Gu, Shenda; Hu, Zhi; Ngamcherdtrakul, Worapol; Castro, David J.; Morry, Jingga; Reda, Moataz M.; Gray, Joe; Yantasee, Wassana.

In: Oncotarget, Vol. 7, No. 12, 22.03.2016, p. 14727-14741.

Research output: Contribution to journalArticle

Gu, S, Hu, Z, Ngamcherdtrakul, W, Castro, DJ, Morry, J, Reda, MM, Gray, J & Yantasee, W 2016, 'Therapeutic siRNA for drug-resistant HER2-positive breast cancer', Oncotarget, vol. 7, no. 12, pp. 14727-14741. https://doi.org/10.18632/oncotarget.7409
Gu S, Hu Z, Ngamcherdtrakul W, Castro DJ, Morry J, Reda MM et al. Therapeutic siRNA for drug-resistant HER2-positive breast cancer. Oncotarget. 2016 Mar 22;7(12):14727-14741. https://doi.org/10.18632/oncotarget.7409
Gu, Shenda ; Hu, Zhi ; Ngamcherdtrakul, Worapol ; Castro, David J. ; Morry, Jingga ; Reda, Moataz M. ; Gray, Joe ; Yantasee, Wassana. / Therapeutic siRNA for drug-resistant HER2-positive breast cancer. In: Oncotarget. 2016 ; Vol. 7, No. 12. pp. 14727-14741.
@article{b5b27c17aafa4c50940a4f34b10903fa,
title = "Therapeutic siRNA for drug-resistant HER2-positive breast cancer",
abstract = "HER2 is overexpressed in about 20{\%} of breast cancers and contributes to poor prognosis. Unfortunately, a large fraction of patients have primary or acquired resistance to the HER2-targeted therapy trastuzumab, thus a multi-drug combination is utilized in the clinic, putting significant burden on patients. We systematically identified an optimal HER2 siRNA from 76 potential sequences and demonstrated its utility in overcoming intrinsic and acquired resistance to trastuzumab and lapatinib in 18 HER2-positive cancer cell lines. We provided evidence that the drug-resistant cancer maintains dependence on HER2 for survival. Importantly, cell lines did not readily develop resistance following extended treatment with HER2 siRNA. Using our recently developed nanoparticle platform, systemic delivery of HER2 siRNA to trastuzumab-resistant tumors resulted in significant growth inhibition. Moreover, the optimal HER2 siRNA could also silence an exon 16 skipped HER2 splice variant reported to be highly oncogenic and linked to trastuzumab resistance.",
keywords = "Breast cancer, Her2, Nanoparticles, SiRNA, Trastuzumab resistance",
author = "Shenda Gu and Zhi Hu and Worapol Ngamcherdtrakul and Castro, {David J.} and Jingga Morry and Reda, {Moataz M.} and Joe Gray and Wassana Yantasee",
year = "2016",
month = "3",
day = "22",
doi = "10.18632/oncotarget.7409",
language = "English (US)",
volume = "7",
pages = "14727--14741",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "12",

}

TY - JOUR

T1 - Therapeutic siRNA for drug-resistant HER2-positive breast cancer

AU - Gu, Shenda

AU - Hu, Zhi

AU - Ngamcherdtrakul, Worapol

AU - Castro, David J.

AU - Morry, Jingga

AU - Reda, Moataz M.

AU - Gray, Joe

AU - Yantasee, Wassana

PY - 2016/3/22

Y1 - 2016/3/22

N2 - HER2 is overexpressed in about 20% of breast cancers and contributes to poor prognosis. Unfortunately, a large fraction of patients have primary or acquired resistance to the HER2-targeted therapy trastuzumab, thus a multi-drug combination is utilized in the clinic, putting significant burden on patients. We systematically identified an optimal HER2 siRNA from 76 potential sequences and demonstrated its utility in overcoming intrinsic and acquired resistance to trastuzumab and lapatinib in 18 HER2-positive cancer cell lines. We provided evidence that the drug-resistant cancer maintains dependence on HER2 for survival. Importantly, cell lines did not readily develop resistance following extended treatment with HER2 siRNA. Using our recently developed nanoparticle platform, systemic delivery of HER2 siRNA to trastuzumab-resistant tumors resulted in significant growth inhibition. Moreover, the optimal HER2 siRNA could also silence an exon 16 skipped HER2 splice variant reported to be highly oncogenic and linked to trastuzumab resistance.

AB - HER2 is overexpressed in about 20% of breast cancers and contributes to poor prognosis. Unfortunately, a large fraction of patients have primary or acquired resistance to the HER2-targeted therapy trastuzumab, thus a multi-drug combination is utilized in the clinic, putting significant burden on patients. We systematically identified an optimal HER2 siRNA from 76 potential sequences and demonstrated its utility in overcoming intrinsic and acquired resistance to trastuzumab and lapatinib in 18 HER2-positive cancer cell lines. We provided evidence that the drug-resistant cancer maintains dependence on HER2 for survival. Importantly, cell lines did not readily develop resistance following extended treatment with HER2 siRNA. Using our recently developed nanoparticle platform, systemic delivery of HER2 siRNA to trastuzumab-resistant tumors resulted in significant growth inhibition. Moreover, the optimal HER2 siRNA could also silence an exon 16 skipped HER2 splice variant reported to be highly oncogenic and linked to trastuzumab resistance.

KW - Breast cancer

KW - Her2

KW - Nanoparticles

KW - SiRNA

KW - Trastuzumab resistance

UR - http://www.scopus.com/inward/record.url?scp=84962886173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962886173&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7409

DO - 10.18632/oncotarget.7409

M3 - Article

C2 - 26894975

AN - SCOPUS:84962886173

VL - 7

SP - 14727

EP - 14741

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 12

ER -